The added influence of genomics and post‐MRI confirmatory biopsy results to MRI results alone on medical decision making for men with favorable risk prostate cancer being considered for active surveillance

We examined how the results of genomic classifier (GC) or post‐magnetic resonance imaging confirmatory biopsy (pMRI‐CBx) influenced management strategy for men with an MRI considering active surveillance (AS).

[1]  Jonathan E. Shoag,et al.  Increasing Utilization of MRI Before Prostate Biopsy in Black and Non-Black Men: An Analysis of the SEER-Medicare Cohort. , 2021, AJR. American journal of roentgenology.

[2]  A. Kishan,et al.  A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. , 2020, European urology.

[3]  H. G. van der Poel,et al.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2020, European urology.

[4]  J. Montie,et al.  Impact of Early Confirmatory Tests on Upgrading and Conversion to Treatment in Prostate Cancer Patients on Active Surveillance. , 2020, Urology.

[5]  J. Brooks,et al.  17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Pond,et al.  Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up. , 2019, European urology.

[7]  Daniel E Spratt,et al.  The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. , 2019, European urology.

[8]  A. D'Amico,et al.  Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  S. Linsell,et al.  Confirmatory Magnetic Resonance Imaging with or without Biopsy Impacts Decision Making in Newly Diagnosed Favorable Risk Prostate Cancer , 2019, The Journal of urology.

[10]  H. Korman,et al.  A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility. , 2019, Urology.

[11]  A. D'Amico,et al.  Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015 , 2019, JAMA.

[12]  A. Turk,et al.  Younger Men With Prostate Cancer Have Lower Risk of Upgrading While on Active Surveillance: A Meta-analysis and Systematic Review of the Literature. , 2018, Urology.

[13]  David C. Miller,et al.  Association Between Early Confirmatory Testing and the Adoption of Active Surveillance for Men With Favorable-risk Prostate Cancer. , 2018, Urology.

[14]  Ronald C. Chen,et al.  Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options , 2017, The Journal of urology.

[15]  S. Lipsitz,et al.  Variation in the use of active surveillance for low‐risk prostate cancer , 2018, Cancer.

[16]  David C. Miller,et al.  A Roadmap for Improving the Management of Favorable Risk Prostate Cancer. , 2017, Journal of Urology.

[17]  M. Parmar,et al.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study , 2018 .

[18]  Mufaddal Mamawala,et al.  Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Danny Vesprini,et al.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Cooperberg,et al.  Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.